Metabolon Launches mView
Biochemical Profiling Service Tailored for Scientists in Academic and Government Institutions
RESEARCH TRIANGLE PARK, NC. (June 4, 2008) – Metabolon, Inc., the leader in metabolomics-driven biomarker discovery and analysis, announced today the availability of mView™, a data-rich biochemical profiling service for scientists in academic and government institutions.
mView will leverage the power of Metabolonís platform technology in a format designed for academic and government labs. Offering online study submission and rapid completion times, mView represents an economical opportunity to answer important biological questions.
"We recognize the unique needs of the academic and government sectors for metabolomic-based analysis. mView is designed to provide these investigators with an affordable, global analysis of hundreds of analytes in a sample," commented John Ryals, chief executive of Metabolon. "A high degree of precision and quick turn-around also helps to achieve important research goals and complete grant submissions."
Metabolonís validated platform technology, the backbone of all Metabolonís services and diagnostic offerings, offers global analysis and identification of hundreds of biochemicals (the metabolome) in complex biological samples. It provides a detailed comparison of how biochemicals change in response to experimental variables as well as sophisticated statistical analysis for detecting significant changes across those biochemicals.
Ryals continued, "As a result of our significant progress in automating the generation of biochemical data, Metabolon is now able to offer the mView service. We believe that this new offering is an important step in bringing practical, cost-effective metabolomic solutions to academic and government researchers."
To submit study specifications, receive detailed pricing and to learn more about Metabolonís mView services offering, please visit www.metabolon.com/services.html. †
Metabolon is a diagnostics and services company
offering the industryís leading biochemical profiling
platform. Metabolonís patented platform provides a
global analysis of complex biological samples for the
discovery of markers and pathways associated with drug
action and disease. This metabolomics-driven approach
enables the identification of biomarkers useful for
the development of a wide range of diagnostics and
provides insight into complex biochemical processes
such as drug action, toxicology and bioprocess
optimization. For more information about Metabolon,
please visit www.metabolon.com.